Physician profile
Lisa A Whims Squires
NPI 1831133446
$11,233.99
in general payments reported to CMS, 2019-2025
26 companies · $2,620 in 2025
The $2,620 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $832 · 2021: $769 · 2022: $2,088 · 2023: $2,163 · 2024: $2,098 · 2025: $2,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,261 · Long Term Medical Supply Or Device Loan: $3,065 · Education: $355 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,260.82 |
| Long Term Medical Supply Or Device Loan | $3,065.29 |
| Education | $354.96 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $4,286.09 | 2019-2025 | (8269) Dreamstation Cpap, Dreamstation Cpap |
| Jazz Pharmaceuticals INC. | $1,928.25 | 2019-2025 | Xywav |
| Harmony Biosciences LLC | $1,663.30 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $928.50 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $510.87 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $440.06 | 2023-2025 | Lumryz |
| Mylan Specialty L.P. | $286.76 | 2021-2024 | Yupelri |
| Axsome Therapeutics, INC. | $159.22 | 2023-2025 | Sunosi |
| Idorsia Pharmaceuticals US INC | $143.42 | 2022-2024 | Quviviq |
| Ucb, INC. | $119.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.47 | 2019-2021 | |
| Fisher & Paykel Healthcare INC | $96.72 | 2019-2024 | Fisher & Paykel Healthcare |
| Resmed Corp | $89.35 | 2022-2025 | |
| Eisai INC. | $89.08 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $79.41 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $54.89 | 2024 | Horizant |
| Merck Sharp & Dohme LLC | $44.52 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.49 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $33.78 | 2019-2021 | |
| Inogen, INC. | $29.74 | 2022 | |
| Aytu Biopharma, INC. | $25.07 | 2020 | |
| Insmed, INC. | $21.87 | 2025 | Arikayce |
| 3b Medical, INC. | $21.17 | 2024 | Luna |
| Viatris Specialty LLC | $19.98 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $16.41 | 2019 | |
| Shionogi INC | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Whims Squires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.